triple reuptake inhibitors (Bristol-Myers Squibb/Albany Molecular Research)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nametriple reuptake inhibitors (Bristol-Myers Squibb/Albany Molecular Research)
Drug Alias Nametriple monoamine reuptake inhibitors (BMS/AMRI)triple monoamine reuptake inhibitors (Bristol-Myers Squibb/Albany Molecular Research)5-HT/norepinephrine/dopamine reuptake inhibitors (BMS/AMRI)biogenic amine uptake inhibitors (Albany Molecular Research Inc/Bristol-Myers Squibb)triple reuptake inhibitors (BMS/AMRI) +[8] 
ClassificationSmall molecules
Mechanisms of ActionSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsDopamine uptake inhibitors +[4] 
TargetsNorepinephrine transporterSerotonin transporter
Therapy Area/IndicationsCentral Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlbany Molecular Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlbany Molecular Research IncBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsCentral Nervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A